Target intelligence / Profile preview

Mitochondrially encoded cytochrome b (MT-CYB)

Target
MT-CYB
Molecular classification
Enzyme, Mitochondrial respiratory chain complex III subunit, Cytochrome b family
01

Overview

Mitochondrially encoded cytochrome b (MT-CYB), commonly known as Cytochrome b, is a critical, mitochondrially encoded subunit of the ubiquinol-cytochrome c reductase complex (Complex III or cytochrome b-c1 complex) located in the inner mitochondrial membrane. It plays an essential role in the mitochondrial respiratory chain by mediating electron transfer from ubiquinol to cytochrome c, which is coupled to proton translocation across the inner membrane to generate the proton-motive force required for ATP synthesis. MT-CYB contains two distinct quinone-binding pockets: the quinol oxidation site (Qo) and the quinone reduction site (Qi). As a therapeutic target, MT-CYB is highly validated for antimicrobial and antiparasitic therapies; for instance, the FDA-approved drug atovaquone targets the Qo site of MT-CYB to treat malaria, pneumocystis pneumonia, and toxoplasmosis. Additionally, MT-CYB is being explored as a target in oncology to inhibit oxidative phosphorylation in cancer stem cells, thereby suppressing tumor growth. However, targeting MT-CYB is associated with challenges, notably the rapid emergence of drug-resistance mutations in pathogens and potential host mitochondrial toxicity.

Other names
Cytochrome bComplex III subunit 3Complex III subunit IIICytochrome b-c1 complex subunit 3Ubiquinol-cytochrome-c reductase complex cytochrome b subunitCYTBCOBMTCYB
02

Mechanism of action

Inhibition of the ubiquinol-cytochrome c reductase complex (Complex III) by binding to the Qo (quinol oxidation) or Qi (quinone reduction) sites within the cytochrome b subunit, thereby blocking electron transfer and ATP synthesis.

03

Biological functions

Mitochondrial electron transportOxidative phosphorylationProton translocationATP synthesis
04

Disease associations

Infection (e.g., Malaria, Pneumocystis pneumonia, Toxoplasmosis)Cancer (e.g., Breast cancer, Bladder cancer)Mitochondrial disease (e.g., Mitochondrial complex III deficiency, Leber hereditary optic neuropathy, Mitochondrial myopathy)
05

Safety considerations

Drug resistance mutations (e.g., G143A, Y268S) that rapidly render inhibitors like atovaquone ineffectiveMitochondrial toxicity and off-target effects on host cells, potentially causing myopathy or lactic acidosisIncreased generation of reactive oxygen species (ROS) upon partial inhibition
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

MT-CYB mutation status (e.g., G143A, F129L, G126S) to predict drug resistanceComplex III enzymatic activityATP levelsReactive oxygen species (ROS) levels

Beyond the preview

Go deeper on Mitochondrially encoded cytochrome b (MT-CYB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrially encoded cytochrome b (MT-CYB).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call